,

Rev Esp Quimioter 2022;35(Suppl.1):64-66

Respiratory infections in Coronavirus disease 2019

JOSE L. DEL POZO

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.15.2022

In the last two years, the capacity of our hospitals has clearly been overwhelmed due to the COVID-19 pandemic The patient who comes to the hospital with a respiratory coinfection does not have the same characteristics as the patient who suffers a superinfection while hospitalized. The number of secondary infections increase proportionally to the severity of the patient’s disease. Besides, pathogens that cause a coinfection are clearly differentiated from the pathogens that cause a superinfection. However, in patients subjected to airway manipulation, superinfections by distinct pathogens can occur. Seventy five percent of patients admitted worldwide with COVID-19 (especially during the first two waves of the pandemic) received some form of antibiotic treatment during admission. In this context, it is essential to develop and implement algorithms that allow us to define the predictors in each individual case for the development of a superinfection.

Rev Esp Quimioter 2022; 35(Suppl. 1):64-66 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):59-63

Immune treatment in COVID-19

ROSARIO MENÉNDEZ, PAULA GONZÁLEZ, ANA LATORRE, RAÚL MÉNDEZ

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.14.2022

Current immune treatment directed to avoid viral replication relies mainly in convalescent plasma and monoclonal antibodies (mAbs). No clinical benefit for convalescent plasma has been reported in a meta-analysis and systematic review compared to standard of care. MAbs are recombinant proteins capable to bind with SARS-CoV-2 preventing its entrance into cells. Several mAbs have shown reduction in viral load and/or progression of the disease such as casirivimab-imdevimab, bamlanivimab-etesevimab and sotrovimab. After the apparition of Omicron variant, it has been reported that sotrovimab retained its activity whereas the other two combinations exhibited loss of neutralizing activity. Several aspects as the target population, timing and doses, serological patient status and evolution of variants still require attention, monitorization and further studies for knowledge gaps.

Rev Esp Quimioter 2022; 35(Suppl. 1):59-63 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):54-58

Steroid therapy and antiviral treatment in SARS-CoV-2 pneumonia: clinical contexts and indications

ANTONI TORRES, CATIA CILLONIZ

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.13.2022

Critically ill patients with COVID-19 face a higher risk of disease progression and complications. The current standard of care includes supportive care measures and fluid management. The Recovery trial observed a reduction in all-cause, 28-day mortality (p<0.001) when patients with COVID-19 requiring oxygen therapy received 6 mg of dexamethasone per day for 10 days. In contrast, in patients not requiring oxygen, no benefit was observed: 28-day mortality rates for the dexamethasone and routine care groups were 17.8% and 14%, respectively. To corroborate these results, the World Health Organization (WHO) performed a meta-analysis. The study showed that the use of systemic corticosteroids compared with routine care placebo was associated with a decrease in all-cause, 28-day mortality. With respect to the effectiveness of remdesivir, the ACTT-1 trial found that the drug conferred a benefit on time to clinical improvement. The subgroup analysis in the clinical trial also showed a benefit per mortality in patients requiring supplemental oxygen, albeit not those in need of mechanical ventilation.

Rev Esp Quimioter 2022; 35(Suppl. 1):54-58 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):50-53

Ventilation support in SARS-CoV-2 pneumonia. Strategy and indications

FEDERICO GORDO, LAURA PARRO, MOHAMED MOHAMED

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.12.2022

The SARS-CoV2 pandemic has generated a need for knowledge, new concepts in pathophysiology and an increase of the use of respiratory support in highly complex patients. This fact has provoked the need to evolve to the concept of personalized ventilatory support according to the patient’s response to treatment.

Rev Esp Quimioter 2022; 35(Suppl. 1):50-53 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):46-49

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam

ROSA Mª GIRÓN, AMPARO IBÁÑEZ, ROSA MAR GÓMEZ-PUNTER, TERESA ALARCÓN

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.11.2022

Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI/REL vs. piperacillin-tazobactam (PIP/TAZ) for treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), demonstrated non-inferiority at all-cause mortality at 28 days (15.9% vs 21.3%), favorable clinical response at 7-14 days end of treatment (61% vs 59.8%) and with minor serious adverse effects (26.7% vs 32%). IMI/REL is a therapeutic option in HAP and VAP at approved dosage imipenem 500 mg, cilastatin 500 mg and relebactam 250 mg once every 6h, by an IV infusion over 30 min.

Rev Esp Quimioter 2022; 35(Suppl. 1):46-49 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):43-45

New evidence in severe pneumonia: meropenem-vaborbactam

MARÍA FORTEZA GUILLOT, MARÍA MARTÍN CEREZUELA, PAULA RAMÍREZ

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.10.2022

The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options. Meropenem-vaborbactam has shown great efficacy against this type of microorganism, both from a clinical and microbiological point of view. Its good pharmacokinetics, including in the lung, and its safety profile make meropenem-vaborbactam an excellent therapeutic option. Finally, the absence of resistance genesis during treatment seems to indicate that its efficacy will be long-lasting.

Rev Esp Quimioter 2022; 35(Suppl. 1):43-45 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):40-42

Ceftazidime-avibactam

FRANCISCO SANZ HERRERO

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.09.2022

The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa, and other enterobacteria. Compared to carbapenems, ceftazidime-avibactam has demonstrated non-inferiority in the treatment of nosocomial pneumonia including better clinical and microbiological cure rates and mortality compared to colistin. The limitation of ceftazidime-avibactam in the treatment of infections caused by metallo-beta-lactamase-producing Enterobacteriaceae can be overcome with the addition of aztreonam.

Rev Esp Quimioter 2022; 35(Suppl. 1):40-42 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):35-39

Ceftolozane-tazobactam in nosocomial pneumonia

FRANCISCO JAVIER CANDEL, JUAN GONZÁLEZ DEL CASTILLO, AGUSTÍN JULIÁN JIMÉNEZ, MAYRA MATESANZ

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.08.2022

Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avoid the mutant selection window specifically in the treatment of Pseudomonas aeruginosa infection. The molecule is time-dependent and stable when reconstituted at room temperature, facilitating safe and effective dosage optimization in frail and critically ill patients. It has been shown to be non-inferior to meropenem in the treatment of nosocomial infection in the ASPECT-NP study but superior in post-hoc studies in the subgroup of patients with ventilator-associated pneumonia, without the emergence of resistance during treatment. It is FDA approved at a dose of 3 g every 8 hours in the treatment of nosocomial pneumonia (HABP/VABP) in adults.

Rev Esp Quimioter 2022; 35(Suppl. 1):35-39 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):31-34

Cefiderocol

MARÍA CRUZ SORIANO, JESSIE MONTUFAR, AARON BLANDINO-ORTIZ

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.07.2022

Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli including Enterobacterales that produce all kinds of carbapenemases and non-fermenting Gram-negative with difficult-to-treat resistance. As a β-lactam, its efficacy is optimized in extended-perfusion and requires dose adjustment in renal dysfunction and hyperclearance. Its efficacy has been validated in three clinical trials, one of them in the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. The clinical trial aimed at difficult-to-treat gram-negatives achieved the clinical and microbiological target, but the increase in mortality observed in the cefiderocol arm makes it necessary to demonstrate efficacy in real clinical practice. Cefiderocol is a good option among the new β-lactams for the treatment of pneumonia caused by Gram-negative bacilli carbapenem-resistant.

Rev Esp Quimioter 2022; 35(Suppl. 1):31-34 [Full-text PDF]


/por
,

Rev Esp Quimioter 2022;35(Suppl.1):28-30

Ceftaroline in severe community-acquired pneumonia

CATIA CILLONIZ, JUAN M PERICÀS, JORGE ROJAS

Published: 22 April 2022

http://www.doi.org/10.37201/req/s01.06.2022

Severe community-acquired pneumonia (SCAP) is associated with high mortality. Factor such as early adequate antibiotic therapy, delay in intensive care unit (ICU) care and pneumonia caused by resistant pathogens are associated with worse outcomes in SCAP patients. Ceftaroline is a fifth-generation cephalosporin with bactericidal activity against Gram-positive pathogens (including methicillin-resistant Staphylococcus aureus [MRSA] and multidrug-resistant Streptococcus pneumoniae) and common Gram-negative organisms. The efficacy and safety for the treatment of pneumonia was evaluated in three randomized control trials were ceftaroline demonstrated superiority against ceftriaxone for the treatment of pneumonia in hospitalized patients with Pneumonia Severity Index (PSI) III – IV.

Rev Esp Quimioter 2022; 35(Suppl. 1):28-30 [Full-text PDF]


/por